Pirche Announces Partnership to Advance Transplant Medicine by Combining Pre-Transplant Risk Stratification and Post-Transplant dd-cfDNA Monitoring
Pirche AG, a leader in digital molecular risk assessment, today announced a new collaboration to advance the field of transplant medicine and immunosuppression. In a strategic collaboration with Natera, Inc., a global leader in cell-free DNA testing and precision medicine, the companies aim to improve patient care by connecting pre-transplant immunological risk assessment with advanced post-transplant molecular monitoring using Natera’s Prospera™ test.
